C-Path Leads Novel Transatlantic Drug Safety Effort; Yields FDA/European Medicines Evaluation Agency Qualification of New Drug Tests for Kidney Safety

TUCSON, Ariz.--(BUSINESS WIRE)--The Critical Path Institute (C-Path) is pleased to announce the first results emanating from a collaboration that was created by C-Path to identify improved methods to test the safety of new drugs in development. This collaboration, the Predictive Safety Testing Consortium (PSTC), is composed of over 200 scientists from the sixteen largest pharmaceutical companies, non-profit research organizations, and advisors from the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).